The Fifth Circuit Court of Appeals has blocked the nationwide mailing of mifepristone, a medication used in abortion procedures. The ruling halts FDA approval that allowed the drug to be dispensed through telehealth and mail services.
Mifepristone ranks among the most widely prescribed abortion medications in the United States. The drug typically works in combination with misoprostol to terminate early pregnancies. The telehealth option dramatically expanded access to medication abortion, particularly for patients in states with restrictive abortion laws.
The Fifth Circuit decision stems from legal challenges brought by anti-abortion groups and some medical professionals who questioned the FDA's original approval process. The court found sufficient grounds to block the mailing provisions while litigation continues.
The FDA now faces review requirements for mifepristone's continued availability. The agency must reassess its prior determination that mail distribution posed acceptable risks.
This ruling affects millions of Americans seeking abortion care outside clinical settings. States without mailing prohibitions still permit in-person dispensing, but the decision constrains access for remote patients. Legal experts expect the case to reach the Supreme Court, where abortion's status remains contested following the overturning of Roe v. Wade in 2022.